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Joint destruction, as evidenced by radiographic findings, is a significant problem for patients suffering from
rheumatoid arthritis and psoriatic arthritis. Inherently irreversible and frequently progressive, the process of joint
damage begins at and even before the clinical onset of disease. However, rheumatoid and psoriatic arthropathies
are heterogeneous in nature and not all patients progress to joint damage. It is therefore important to identify
patients susceptible to joint destruction in order to initiate more aggressive treatment as soon as possible and
thereby potentially prevent irreversible joint damage. At the same time, the high cost and potential side effects
associated with aggressive treatment mean it is also important not to over treat patients and especially those who,
even if left untreated, would not progress to joint destruction. It is therefore clear that a protein biomarker
signature that could predict joint damage at an early stage would support more informed clinical decisions on the
most appropriate treatment regimens for individual patients. Although many candidate biomarkers for rheumatoid
and psoriatic arthritis have been reported in the literature, relatively few have reached clinical use and as a
consequence the number of prognostic biomarkers used in rheumatology has remained relatively static for several
years. It has become evident that a significant challenge in the transition of biomarker candidates to clinical
diagnostic assays lies in the development of suitably robust biomarker assays, especially multiplexed assays, and
their clinical validation in appropriate patient sample cohorts. Recent developments in mass spectrometry-based
targeted quantitative protein measurements have transformed our ability to rapidly develop multiplexed protein
biomarker assays. These advances are likely to have a significant impact on the validation of biomarkers in the
future. In this review, we have comprehensively compiled a list of candidate biomarkers in rheumatoid and psoriatic
arthritis, evaluated the evidence for their potential as biomarkers of bone (joint) damage, and outlined how mass
spectrometry-based targeted and multiplexed measurement of candidate biomarker proteins is likely to accelerate
their clinical validation and the development of clinical diagnostic tests.Introduction
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are
the most prevalent forms of inflammatory arthritis affect-
ing ~1 % and ~ 0.3 to 1 % of the population, respectively
[1, 2]. Disease aetiology is unknown but it is thought that
both genetic and environmental factors trigger the onset of
these arthropathies [3]. The onset of RA and PsA is clini-
cally recognised when a patient presents with symptoms
fulfilling disease classification criteria, importantly the
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stated.the Classification for Psoriatic Arthritis CASPAR criteria
[4, 5]. However, it is recognised that disease onset may
occur much earlier, even prior to symptom onset [6, 7].
Several disease-specific characteristics differentiate RA
from PsA. For example, rheumatoid factor (RF) is present
often at high titre in 80 % of RA patients whereas it is
present at low titre in only 13 % of PsA patients. PsA
is included among the spondylarthopathies because it
shares both clinical features and association with HLAB27
with other spondylarthopathy members. The presence of
psoriasis is a hallmark of PsA, although joint involvement
may precede skin manifestations in ~10 % of patients.
Asymmetric joint involvement is seen commonly in PsA
whereas joint involvement in RA follows a symmetrical
pattern. Dactylitis, enthesitis, sacroiliitis and interphalan-
geal joint involvement are also more common in PsA [3].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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important differences between synovial tissue in RA and
PsA [8]. Angiogenesis is dysregulated in both conditions
and abnormal vessel morphology and function has been
reported. Increased straight, branching vascularisation is
a prominent feature observed in RA joints, whereas the
formation of elongated, bushy, torturous blood vessels is
a more marked feature of the PsA joint [8, 9]. In the RA
joint there is increased macrophage infiltration and sub-
sequent synovial invasion compared with that observed
in PsA. As a result, lining layer hyperplasia observed in
RA is more striking than that observed in PsA [3]. Con-
versely, PsA is characterised by more extensive infil-
tration of polymorphonuclear cells [8]. It has been
reported that the extent of T-cell and B-cell infiltrationFig. 1 Synovitis in rheumatoid arthritis and psoriatic arthritis. Synovitis in rh
unknown event(s). It is thought that a genetic predisposition and/or enviro
promoting an autoimmune inflammatory response. Once activated, synovi
proximal cells, including endothelial cells that line the blood vessels supply
increased infiltration of leukocytes, including monocytes, macrophages, neu
produce cytokines that act in synergy to propagate the inflammatory respo
(IL)-17 are cytokines with major implied roles in PsA and RA pathogenesis
a chronic inflammatory response, the synovial lining becomes hyperplastic
promotes the destruction of cartilage and bone. Activation of osteoclast ce
promotes bone proliferationis comparable in both conditions and the formation of
germinal centres (zones of T-cell and B-cell prolifera-
tion) are observed in both PsA and RA joints [8, 10, 11].
The differences in synovitis in RA and PsA are illus-
trated in Fig. 1.
Radiographic progression
Radiographic progression is considered a consequence
of synovial inflammation. However, at least for RA, the
observations that bone loss can occur before clinical onset
and at very early stages of disease have been widely ac-
knowledged [6, 7]. These observations are surprising since
synovitis requires some time to destroy bone to an extent
that is clinically detectable. Synovitis might thus not
be the exclusive cause of joint damage. An alternativeeumatoid arthritis (RA) and psoriatic arthritis (PsA) is triggered by
nmental cues trigger inappropriate activation of synoviocytes, thereby
ocytes produce proinflammatory cytokines that in turn activate
ing the joint. This results in dysregulated angiogenesis and the
trophils, mast cells, eosinophils, B cells and T cells. Infiltrating cells
nse. Importantly, tumour necrosis factor alpha (TNFα) and interleukin
and represent important therapeutic targets. With the development of
. Fibroblasts and macrophages form an invasive matrix (pannus) that
lls promotes bone resorption whereas activation of osteoblasts
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before the clinical onset of disease and that these pro-
cesses promote joint destruction. Indeed, levels of anti-
citrullinated protein antibodies (ACPA) can be detected in
RA years before the clinical onset of disease. A compara-
tive imaging study used micro computerised tomography
to assess bone densities in healthy individuals that were ei-
ther positive or negative for ACPA. The ACPA-positive in-
dividuals exhibited significant alterations in cortical bone
architecture as compared with the ACPA-negative individ-
uals. These findings support the theory that bone damage
is not exclusively a consequence of synovitis [7].
Previously, PsA was believed to be a mild nonprogres-
sive form of arthritis. However, it is now well understood
that 47 % of PsA patients will develop erosions within 2
years of symptom onset, and that of the patients suffer-
ing from polyarticular PsA at least 20 % are at risk of
progressing to a severe destructive phenotype (mutilans)
comparable with that observed in RA [12]. What is
more, bone changes observed in PsA are particularly
heterogeneous both between and also within individual
sufferers (Fig. 2). X-ray images are used in the clinic to
follow radiographic progression and may be scored to
measure the extent of joint damage. The Sharp–van der
Heijde scoring method is most commonly used toFig. 2 X-ray image of changes in bones observed in psoriatic
arthritis. Bone changes in psoriatic arthritis (PsA) patients may differ
between patients and may also differ within the same patient. The
heterogeneity observed within a PsA patient is illustrated. Left-hand
radiograph from a PsA patient showing severe erosive disease and
subluxation at the first distal interphalangeal (DIP) with fluffy periosteal
new bone formation on the terminal phalange. Ankylosis of the second
DIP joint is also demonstratedmeasure joint damage in RA. This method provides sep-
arate scores for erosion and joint space narrowing in the
hands, wrists and feet. A modified Sharp–van der Heijde
score is used to measure radiographic progression in
PsA where the distal interphalangeal joints of the hands
are also included [13, 14].
While X-ray imaging is the best validated technique for
detecting bone erosion, it is limited by its two-dimensional
character. Additional imaging modalities such as magnetic
resonance imaging, micro computerised tomography and
ultrasound are utilised to identify distinguishing features
between RA and PsA. Radiographic progression in RA and
PsA is remarkably different. RA is a bone-resorbing, ero-
sive disease whereas the pattern of radiographic progres-
sion in PsA is more complex. As in RA, bone resorption
and erosion may be evident in PsA, but radiographic pro-
gression may also be marked by more severe resorption or
osteolysis and commonly bony proliferation is prominent.
To the best of our knowledge early protein biomarkers of
bone proliferation have not yet been reported in the litera-
ture, but these markers will probably differ from bio-
markers of erosion. Distinguishing patterns of disease
progression in RA and PsA have been captured by differ-
ent imaging modalities and are summarised in Table 1.
Biomarkers
Molecular events that drive joint damage may precede dis-
ease onset and can cause detrimental long-term effects
such as disability [6, 7, 10, 15, 16]. It is therefore essential
to begin therapy as soon as possible in order to prevent ir-
reversible damage. Some of the therapies currently avail-
able are associated with high cost and potential for side
effects. Additionally, up to 40 % of patients will not meet
the primary outcome measure and, in those who do re-
spond, levels of disease activity can remain significant. To
add to the complexity, not all patients will develop a de-
structive form of disease. Aggressive treatment should
thus be reserved for patients that will develop a more se-
vere form of disease [17]. In light of this, the need to de-
velop biomarker signatures predictive of joint damage in
RA and PsA is of critical importance. Currently there is a
major international effort driven by the Outcome Mea-
sures in Rheumatology Clinical Trials and the Group for
Research and Assessment in Psoriasis and Psoriatic Arth-
ritis well underway in RA and to start soon in PsA
whereby biomarker samples are being prospectively col-
lected in an effort to identify predictors of radiographic
damage.
Biomarkers serve as objective molecular indicators of
pathological processes such as the development of joint
destruction. Owing to the heterogeneous nature of RA
and PsA, identifying a single biomarker predictive of
joint damage would be an onerous task. Indeed, no sin-
gle biomarker has so far emerged as a reliable predictor
Table 1 Radiological features that distinguish between rheumatoid arthritis and psoriatic arthritis
Disease feature Rheumatoid arthritis Psoriatic arthritis Imaging technique Reference
Number of erosions +++ + X-ray [18]
+++ +++ μCT [82]
Severity of erosions +++ ++ μCT [83]
Shape of erosions
Ʊ + +++ μCT [83]
Tubule + +++ μCT
U +++ + μCT
Erosion distribution Preponderance for radial sites Evenly distributed μCT [83]
DIP joint erosion – +++ US, MRI, X-ray [84]
Number of osteophytes + +++ μCT [82]
Severity of osteophytes (size) + +++ μCT [82]
Bone proliferation + +++ US, MRI, X-ray [84]
Inflammatory changes
Synovitis +++ ++ MRI, US [84]
Tenosynovitis +++ ++ MRI, US [84]
Enthesitis + +++ MRI, US [85]
Dactylitis – +++ US, MRI [86]
Mutilans (erosions on both sides of joints) + X-ray [87]
Disease features present in RA and PsA and the radiological imaging technique used to measure the feature. The number of erosions observed in RA appears to
be greater than that in PsA. However, more sophisticated higher resolution techniques reveal this is not accurate because erosions in PsA are generally smaller
and their detection requires these more sensitive techniques. Hence, μCT reveals a comparable extent of bone erosion in RA and PsA. MRI and US capture
differences in sites affected by inflammation in these disorders. In PsA it is the enthesis that are major sites of inflammation, whereas in RA the synovium
becomes chronically inflamed. Inflammation of the tendons is also prevalent in both disorders although more severe in RA. Distinct features of PsA include bony
proliferation, and dactylitis. DIP, distal interphalangeal; μCT, micro computational tomography; MRI, magnetic resonance imaging; PsA, psoriatic arthritis; RA,
rheumatoid arthritis; US, ultrasound
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interest in identifying a panel of biomarkers that could
be incorporated into a signature predictive of disease
progression. Such a signature could be used as an indi-
cator of joint destruction and thus facilitate clinicians in
making more informed clinical decisions and help guide
personalised medical approaches [18, 20]. It is important
to recognise that joint destruction contributes signifi-
cantly to disability in patients suffering from inflamma-
tory arthritis, but it is not the sole cause of disability.
Joint inflammation, swelling, pain and disability occur in
the absence of joint destruction [21]. In PsA, for ex-
ample, there are many debilitating phenotypes of disease
but not all PsA phenotypes include bone erosion [22]. It
would be useful to have a biomarker that distinguishes
between different disease phenotypes (for example, pro-
gressors from nonprogressors). Such a biomarker would
help inform the clinical decision of whether to treat
symptoms only or to adopt a more aggressive treatment
strategy in order to prevent radiographic progression.
The aim of this review is to identify previously published
reports that include proteins predictive of joint damage at
early disease time points. Joint damage is most definitively
measured by radiographic progression. Hence this reviewis limited to observational prospective cohort studies that
used radiographic progression as a measure of joint de-
struction and included patients with early-stage disease at
baseline. Observational studies are considered inferior to
randomised control trials due to the fact that results can
be influenced by confounding factors such as a patient’s
response to therapy. Biomarkers predictive of joint dam-
age at baseline in a treatment-naïve patient may not be
predictive after initiation of therapy due to the suppressive
effect of the pharmacological intervention on inflamma-
tory mediators. However, evidence derived from well-
designed prospective cohort studies that follow patients
longitudinally and correct for confounding factors is con-
sidered important in the clinical decision-making process
and is comparable with that provided by randomised con-
trol trials [23, 24]. Limiting this approach, there is a pau-
city of early cohort studies in PsA in which radiographic
progression is measured. As disease activity and changes
in tissue organisation may serve as surrogate measures of
joint damage, we have included soluble biomarkers that
correlated with these disease parameters in the PsA stud-
ies reviewed. In addition, the potential opportunities
afforded by new mass spectrometry-based protein meas-
urement approaches will be highlighted. These methods
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potential to change dramatically the landscape of protein
biomarkers.
Biomarkers of joint damage in rheumatoid
arthritis
Markers of the acute phase response
Inflammation in the synovium is reflected by a systemic
inflammatory response. Increased erythrocyte sedimen-
tation rate (ESR) and hepatocyte production of acute
phase proteins including C-reactive protein (CRP) and
acute phase serum amyloid A (A-SAA) are surrogate
markers of this process. The acute phase response has
been considered important in the context of RA as it
mirrors synovial inflammation. CRP and the ESR have
been shown to correlate with radiographic progression
and these indices have been incorporated into composite
scores typically used to predict damage. However, these
are general markers of inflammation; they are not dis-
ease specific. Furthermore, CRP and the ESR remain
normal in a proportion of RA patients that may progress –
and thus additional and more sensitive predictors are re-
quired. One RA cohort study which incorporated patients
with a range of disease durations showed that A-SAA cor-
related with radiographic progression. It would be interest-
ing to investigate the correlation of A-SAA with joint
damage in an early cohort as this protein reflects not only
systemic but also local inflammation [25].
Auto-antibodies
Auto-antibodies such as RF and ACPA are very useful
prognostic markers in RA. It has previously been re-
ported that patients positive for ACPA or RF are more
likely to develop erosions compared with those who are
negative for both. Additionally it was reported that those
who were positive for ACPA and negative for RF were
more likely to progress to a severe disease state com-
pared with those who were RF-positive but ACPA-
negative. Furthermore it was noted that patients positive
for both ACPA and RF were at greatest risk of disease
progression [26–28]. ACPA emerge as the most useful
indicator of joint damage. Indeed, RF is quite limited in
its ability to predict damage because this antibody is not
disease specific. Moreover RF is considered useful only
at early disease time points, and its predictive power is
lost as disease progresses. In contrast, in addition to
being more sensitive, ACPA are more disease specific
and useful at both early and later disease time points
[26, 29]. There exist, however, subgroups of patients
who are susceptible to joint damage but who test nega-
tive for both RF and ACPA. Since RF and ACPA have
been proven very useful indicators of damage, the identi-
fication of novel auto-antibodies may prove advanta-
geous especially in patients who lack RF and ACPA. Itwas reported recently that a distinct family of auto-
antibodies which recognise carbamylated antigens, the
anti-carbamylated protein antibodies, are predictive of
a severe disease course in early RA patients even after
correction for RF and ACPA. It was demonstrated that
patients who were positive for immunoglobulin G anti-
carbamylated protein antibodies but negative for ACPA
developed a more severe disease course compared with
patients who were ACPA-positive only. Those who
were positive for both anti-carbamylated protein anti-
bodies and ACPA were comparable in severity [30].
Anti-carbamylated protein antibodies might thus prove
a useful biomarker in RA, and their ability to predict
joint damage warrants further research.
Cytokines and chemokines
Cytokines play a major role in promoting joint damage
and their association with radiographic progression has
been investigated in several early RA cohort studies. It
has been reported separately that elevated levels of inter-
leukin (IL)-6, IL-16, IL-22, IL-33, chemokine ligand
(CCL)11 and chemokine (C-X-C) motif ligand (CXCL)13
are predictive of radiographic progression [31–35]. The
finding that IL-6 was associated with joint damage is
controversial, however, and contradictory findings have
been reported. Klein-Wieringa and colleagues demon-
strated that elevated levels of IL-6 were not significantly
correlated with radiographic progression in an early RA
cohort [36]. This is in disagreement with Knudsen and
colleagues, who demonstrated that IL-6 was a strong in-
dependent predictor of radiographic progression [31].
These controversial findings might be explained in part
by differences in study design. Klein-Wieringa and
colleagues measured serum levels of IL-6 in a large RA
cohort consisting of 253 patients. Patients enrolled in
this study received three different treatment strategies.
Radiographic progression was assessed over 4 years using
the Sharp–van der Heijde scoring method. Multivariate
regression analysis was used to find an association be-
tween levels of IL-6 and disease progression. This model
corrected for confounding factors including therapeutic
intervention. In contrast, Knudsen and colleagues mea-
sured plasma levels of IL-6 in a smaller RA cohort consist-
ing of 51 patients and treatment change was permitted
over the duration of the study. Radiographic progression
was measured using the Larsen method. Levels of IL-6
were measured 13 times over 2 years and the mean con-
centration (area under the curve) of IL-6 measurements
over 24 months were used to associate levels of IL-6 with
bone erosions observed at 12 and 24 months [31, 36].
Conversely, a study by van Leeuwen and colleagues dem-
onstrated that elevated levels of plasma IL-6 were not pre-
dictive of damage [37]. However, the IL-6 assay used
during this study was less sensitive than that used by
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relation to IL-6 highlight the impact of study design on
reported findings in the literature. Single reports provide
evidence that IL-16, IL-22, IL-33, CCL11 and CXCL13
retain prognostic capacity in early RA. It was interest-
ing to note that CCL11 was associated with reduced
radiographic progression and thus may have a protect-
ive role during pathogenesis [33]. Additional studies
should be carried out to validate the finding that the
aforementioned molecules independently correlate with
radiographic progression.
Adipokines
Adipokines are cytokines produced by fat cells. These
proteins are elevated in patients with RA, where they are
thought to have potent immunomodulatory effects. A
study by Rho and colleagues demonstrated that adipo-
nectin, visfatin and leptin correlated with measures of
radiographic progression. Adiponectin and visfatin were
shown to correlate with increased radiographic progres-
sion, whereas leptin was associated with reduced pro-
gression [38]. Klein-Wieringa and colleagues confirmed
the finding that adiponectin is predictive of radiographic
progression in patients with early RA [36].
Calprotectin
Calprotectin is released from activated leukocytes that
derive mainly from the inflamed synovium in RA pa-
tients. A recent cohort study by Hammer and colleagues
demonstrated that RA patients with higher baseline
levels of calprotectin developed more severe radio-
graphic damage after 10 years compared with patients
with lower levels of calprotectin. Furthermore, calprotec-
tin levels measured at baseline and at 10 years signifi-
cantly correlated with radiographic damage after 10
years. The correlation observed for calprotectin was
similar to that observed for CRP and ESR [39]. Taken
together these results can lead to the conclusion that
calprotectin is more specific and just as sensitive at pre-
dicting joint damage as CRP and may provide valuable
information in the context of a biomarker signature pre-
dictive of joint damage.
Markers of angiogenesis
Angiogenesis is central to the development of RA syno-
vitis and thus assessing levels of angiogenic markers in RA
patients may prove useful for predicting joint damage.
Vascular endothelial growth factor (VEGF) is thought to
be the most important mediator of angiogenesis and there
is good evidence to suggest that this molecule should be
considered a candidate marker of joint damage in RA
[40, 41]. A study by Ballara and colleagues demonstrated
in early RA that elevated VEGF levels at inclusion signi-
ficantly correlated with radiographic progression after 1year [41]. Clavel and colleagues confirmed the finding that
VEGF was predictive of joint damage in early RA patients.
Additional analysis revealed that VEGF levels at inclusion
were correlated with initial Sharp scores and Sharp scores
measured after 1 year. It was also demonstrated that levels
of angiopoeitin-1 (a marker of angiogenesis) were predict-
ive of damage at inclusion and after 1 year. This finding
suggests that VEGF and angiopotietin-1 remain predica-
tive at later disease stages after initiation of therapy [40].
Products of collagen degradation
Fragments released as a result of type I and type II colla-
gen degradation – including C-terminal telopeptide of col-
lagen (CTX)I and CTXII, collagen type II degradation
product epitopes C2C and C1,2C as well as matrix pro-
teins such as cartilage oligomatrix protein (COMP) – are
reflective of bone and cartilage damage. Several studies
have investigated the association of these molecules with
radiographic progression in early RA patients. Three au-
thors reported that elevated levels of CTXI and CTXII are
associated with long-term radiographic progression in
early RA patients [42–44]. What is more, Garnero and
colleagues reported that CTXI and CTXII were even more
predictive of joint damage compared with CRP and ESR
[42]. Bakker and colleagues found that elevated baseline
levels of C1,2C were associated with radiographic progres-
sion after 1 year of treatment [45]. Additionally Verstappen
and colleagues demonstrated that C2C significantly corre-
lated with radiographic progression after 1 year and im-
portantly remained predictive the following year [46].
Andersson and colleagues demonstrated that increments
in COMP levels during a 3-month period following diag-
nosis were predictive of joint damage at 1-year, 2-year and
5-year follow-up [47]. The culmination of positive findings
makes these degradation products attractive candidates for
a biomarker panel predictive of joint damage.
Enzyme mediators of destruction
The association of matrix metalloproteinase (MMPs), pro-
teases that promote cartilage breakdown, with joint dam-
age has also been investigated. Previous early RA cohort
studies demonstrated that elevated levels of MMP-3 at
baseline correlate significantly with radiographic progres-
sion [48–50]. However, another study documented that
serial, longitudinal measurements of MMP-3 fail to correl-
ate with measures of joint damage [51]. It can thus be
speculated that MMP-3 may be a useful predictive marker
of joint destruction at disease onset prior to treatment.
MMP-1 might also have prognostic utility and its associ-
ation with joint damage has been assessed. Previously, ele-
vated baseline levels of MMP-1 were demonstrated to
significantly correlate with radiographic progression ob-
served at 12 months [49]. It has also been reported that
serial measurements of MMP-1 over a period of 18
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age [51]. In contrast, Young-Min and colleagues found no
correlation between levels of MMP-1 and joint damage in
early RA patients [50]. It is certainly possible that differ-
ences in study design and data analysis gave rise to these
discrepancies, and the relationship between MMP-1 and
joint damage warrants further investigation.
Biomarkers of joint damage in psoriatic arthritis
Cytokines
The cytokine expression profile in the PsA synovium is
relatively similar to that observed in RA [8]. IL-17 has
emerged as an important cytokine in autoimmune dis-
eases and this protein in synergy with tumour necrosis
factor alpha contributes to pathogenesis in RA and PsA.
It has previously been demonstrated that, compared with
osteoarthritic controls, levels of IL-17 are elevated in the
synovial tissue of patients with PsA and RA (no signifi-
cant difference between the two). It was also demon-
strated that in vitro stimulation of synovial tissue with
IL-17 induced proteins involved in matrix turnover and
cartilage destruction [52].
There are very few studies reporting the association of
soluble cytokines with joint damage in PsA. However,
cytokines that segregate patients with polyarthritis from
those with oligoarticular disease have been identified. In
an early PsA cohort, elevated levels of IL-1 were detected
in the synovial fluid of polyarthritic patients compared
with those with monoarthritis, suggesting that this protein
is a marker of disease progression [53]. A Norwegian co-
hort found that elevated levels of IL-12p40, interferon
alpha, IL-15 and CCL3 could segregate PsA patients with
polyarticular disease from those with oligoarticular disease
[54]. Since patients with polyarthritis have more severe
joint involvement, these molecules might drive progres-
sion and would be interesting to investigate in the context
of early PsA.
Calgranulin (S100A8/S100A9)
A study by Kane and colleagues demonstrated that ele-
vated levels of calgranulin (S100A8/S100A9) correlated
with measures of disease activity and markers of intra-
articular inflammation (white blood cell counts). The
study further demonstrated that treatment with metho-
trexate resulted in a significant decrease in S100A8/
S100A9 levels. A significant reduction in swollen joint
count, Richie articular index and Disease Activity Score
was also observed after treatment, suggesting that S100A8/
S100A9 may also correlate with joint damage in PsA [55].
Additional evidence reporting an association between
S100A8/S100A9 with progressive disease exists. A study
by Aochi and colleagues demonstrated that S100A8/
S100A9 levels in PsA patients (disease duration not speci-
fied) with more than 10 affected joints were highercompared with levels in those who had less than 10 af-
fected joints [56]. These results together suggest that
S100A8/S100A9 may be associated with joint damage and
that this marker might provide additional information in
the context of a biomarker signature.
Markers of angiogenesis
The ability of angiogenic markers to predict joint dam-
age in RA has been reported [41, 57]. Abnormalities in
angiogenesis are more pronounced in PsA compared
with RA and levels of VEGF and angiopotietin-2 have
been reported to be higher during PsA relative to RA
[56]. It is thus logical to conclude that these molecules
could act as early markers of radiographic progression,
but there is a lack of data in the literature to validate this
hypothesis. Interestingly, the association of VEGF with
active versus inactive disease and with changes in syn-
ovial vascular morphology has been described [56–58].
Molecules that regulate bone turnover
Dalbeth and colleagues examined the association between
soluble mediators of bone remodelling (receptor activator
of nuclear factor-κB ligand, osteoprotegerin, wnt signalling
pathway inhibitor-1, macrophage colony-stimulating fac-
tor) with radiographic progression in PsA patients with
established disease duration. A positive correlation be-
tween macrophage colony-stimulating factor and receptor
activator of nuclear factor-κB ligand concentrations with
radiographic progression was described [59]. Connolly
and colleagues found that baseline levels of A-SAA were
independently associated with 1-year radiographic pro-
gression in PsA patients with long disease duration. A-
SAA promotes the production of MMPs by fibroblast-like
synoviocytes. A-SAA levels were demonstrated to correl-
ate with MMP-1, MMP-3, MMP-13 and MMP/tissue in-
hibitor of matrix metalloproteinases [25]. Since it has been
demonstrated previously that MMP-1 and MMP-3 are as-
sociated with radiographic progression in early RA, it
could be speculated that an association between A-SAA
and MMPs might correlate with radiographic progression
in early PsA – this warrants further research.
An emerging mass spectrometry technology
The development of a protein biomarker identified in
discovery experiments for clinical assay is both long
and challenging [60]. The clinical validation of candidate
biomarkers has traditionally relied on the development of
antibody-based assays. Enzyme-linked immunosorbent
assays (ELISAs) are one of the most widely used
methods for clinical diagnostic protein biomarker mea-
surements [61, 62].
Large numbers of candidate biomarkers are emerging
and it has become apparent that an alternative technology
is required to evaluate them in a time- and cost-effective
Mc Ardle et al. Arthritis Research & Therapy  (2015) 17:141 Page 8 of 12manner [63, 64]. The relatively recent introduction of a
multiple reaction monitoring (MRM) mass spectrometry
platform for the measurement of peptides has provided
the opportunity to develop multiplexed assays for simul-
taneously measuring multiple candidate biomarkers and
to progress them through the biomarker development
pipeline [65]. There are a number of key drivers for the
adoption of MRM as a viable alternative to the traditional
antibody-based approach. The economics of MRM ana-
lysis far outweigh methods requiring antibodies (western
blot or ELISA). Good antibodies are relatively expensive
and in some cases not always available for the proteins of
interest. Even for proteins for which antibodies are avail-
able, the length of time needed to optimise an assay using
MRM mass spectrometry is much shorter relative to that
using antibody-based protein detection [63, 64].
MRM assays are developed for peptides released from
proteolytically cleaved proteins. A peptide that is unique
to the protein of interest (a proteotypic peptide, gener-
ally ranging from 7 to 25 amino acids in length) and that
is routinely observed by the mass spectrometer is crucial
to guaranteeing accurate detection of specific proteins
[66]. By measuring only selected proteotypic peptides,
the abundance of selected proteins can be definitively
established [65, 67, 68]. In MRM mode, only those pep-
tides of interest pass through the mass spectrometer by
setting the first quadrupole to filter based on the known
mass/charge ratio of the peptide. In the second quadru-
pole the peptides are then fragmented and will produce
fragments of known size. The third quadrupole is then
used to filter these fragments, allowing them to pass to a
detector. The prior knowledge of peptide sequences is
used to direct the mass spectrometry in MRM mode.
The triple-quadrupole mass spectrometer can be set to
filter hundreds of peptides in the first quadrupole and
thousands of peptide fragments (transitions) in the third
quadrupole, thereby enabling many proteins to be mea-
sured. Therefore, for example, in a typical analytical run
(<30 minutes) it is possible to measure hundreds of
peptides [69, 70], which is analogous to performing
hundreds of western blot analyses or ELISAs within a
30-minute timeframe. Indeed the MRM approach has
been implemented in several large-scale biomarker
studies over the past couple of years. These assays have
so far proved particularly useful in the field of toxicol-
ogy and oncology [71–73]. This technique has not yet
been exploited to its full potential in rheumatology, but
evidence supporting its potential utility does exist. For
example, an MRM assay was developed for CRP and
this assay was then used to distinguish progressive from
nonprogressive arthritic patients [74]. More recently,
Ademowo and colleagues developed an MRM assay
for a panel of 57 synovial tissue proteins. This assay
was then used to predict PsA patients who respondedwell to therapy compared with those who did not re-
spond [75].
Luminex technology is another example of a multiplex
platform for biomarker validation. This technology is
based on polystyrene beads that are coated with specific
capture antibodies and impregnated with dyes of differ-
ent intensities. Interrogation of the beads with lasers re-
sults in the identification of a bead and hence an analyte
due to its unique spectral properties [76]. The luminex
is cable of measuring proteins that span a low dynamic
range (<103) which would not be detected by MRM. In
addition to being a high-throughput assay, the sensitivity
and specificity of the luminex technique is comparable
with the ELISA [77, 78]. This technology is limited, how-
ever, by availability of antibodies against proteins of
interest, high cost and the quantity of sample required
for analysis [78].
Conclusions
In relation to what has been shown to date, considerably
more candidate biomarkers have been identified in RA
compared with PsA (Table 2). No single biomarker has
been validated as a potent predictor of joint damage and
it is well recognised that a multi-biomarker panel is
needed to compensate for the heterogeneity between in-
dividuals. A multi-biomarker panel incorporating 12
serum proteins has been shown to accurately reflect dis-
ease activity in RA [18]. This panel of proteins may be
measured using a blood-based test referred to as a
multi-biomarker disease activity (MBDA) test. Concen-
trations of the 12 biomarkers are incorporated into an
algorithm that provides a low, moderate or high disease
activity score as an output [18]. A recent study has
shown that the MBDA test correlates well with measures
of CRP, but there may also be discordance between
levels of CRP and the MBDA test. In patients with both
low levels of CRP and a low MBDA score, radiographic
progression is infrequent. In contrast, in patients with
low levels of CRP but a high MBDA score, a significant
proportion developed radiographic progression during 1
year of follow-up. Levels of the multi-biomarker panel
(which include CRP) thus better predict radiographic
progression than CRP alone [79]. In a further study the
MBDA test has been shown to predict risk of radio-
graphic progression and outperform CRP as a predictive
biomarker in the SWEFOT cohort trial. In this trial, only
patients with a high MBDA score were at risk of devel-
oping radiographic progression. In contrast, a substantial
proportion of patients with low, moderate and high
levels of CRP were at risk of developing joint damage
[80]. Finally, the ability of the MBDA score to predict
joint damage has been demonstrated in an additional
trial that included 163 patients from the Leiden Early
Arthritis Cohort. The MBDA score and the Disease
Table 2 Candidate biomarkers of joint damage in rheumatoid arthritis and psoriatic arthritis
Candidate biomarker Evidence for role in inflammatory arthritis Use
Inflammatory proteins
C-reactive protein Opsonisation and compliment activation RA
Calprotectin (S100A12) Ca2+ binding protein released upon phagocyte activation, important intracellular and extracellular roles RA/PsA
Calgranulin (S100A8/S100A9) Ca2+ binding protein with pleotropic effects. Regulates myeloid derived cells PsA
A-SAA Promotes the production of MMPs RA/PsA
Cytokines
IL-1 Promotes activation of keratocytes, endothelial cells, chondrocytes and osteoclasts. Promotes the production of
proinflammatory cytokines
PsA
IL-6 Promotes neutrophil chemotaxis and production of proinflammatory cytokines, induces an acute phase response RA
IL-13 Promotes antibody production by B cells RA
IL-15 Induces T cell proliferation and B cell differentiation. Recruits memory T cells to the synovium and induces TNFα production PsA
IL-16 Promotes chemotaxis of CD4+ T cells, monocytes and eosinophils. Modulates T-cell activation RA
IL-22 Induces proliferation of fibroblasts and production of MCP-1 (monocyte chemokine) RA
IL-33 Promotes chronic inflammatory response RA
Chemokines
CCL3 Lymphocyte, monocyte, basophil, eosinophil chemoattractant PsA
CCL11 Eosinophil chemoattractant PsA
CXCL13 B-cell chemoattractant RA
Adipokines
Adiponectin Induces IL-6 and MMP-1 production by SLFs. Promotes IL-6, TNFα and MCP-1 production in chondrocytes RA
Visfatin Role unclear, thought to modulate inflammation RA
Markers of angiogenesis
VEGF Potent inducer of angiogenesis and vascular permeability RA/PsA
Angiopotietin-1 Promotes angiogenesis (growth of new blood vessels) RA
Angiopotietin-2 Promotes angiogenesis PsA
Auto-antibodies
Rheumatoid factor Forms immune complexes, promotes complement activation and formation of rheumatoid nodules RA
Anti-CCP Promotes complement activation RA
Anti-Carp Bind homocitrulline containing proteins RA
Enzyme mediators of destruction
MMP-1 Degrades collagen RA
MMP-3 Degrades collagen RA
Regulators of bone remodelling
RANKL Induces osteoclast bone destruction PsA
M-CSF Induces aggressive phenotype in macrophages PsA
Products of collagen degradation
COMP Cartilage oligomatrix protein RA
CTXI C-terminal telopeptide of collagen type I RA
CTXII C-terminal telopeptide of collagen type I RA
C1,2C Collagen type II degradation product RA
C2C Collagen type II degradation product RA
Candidate biomarkers predictive of joint damage in RA and PsA have been identified in the literature. These include inflammatory proteins, cytokines, chemokines,
adipokines, markers of angiogenesis, auto-antibodies, enzyme mediators of destruction, molecules that regulate bone turnover and products of collagen degradation.
For references see text. A-SAA acute-phase serum amyloid A; anti-Carp, anti-carbamylated protein antibodies; CCL, chemokine ligand; CCP, cyclic citrullinated peptide;
CXCL, chemokine (C-X-C) motif ligand; IL, interleukin; M-CSF, macrophage colony stimulating factor; MCP-1, monocyte chemoattractant protein-1; MMP, matrix
metalloproteinase; RA, rheumatoid arthritis; PsA, psoriatic arthritis; RANKL, receptor activator of nuclear factor-κB ligand; SLF, synovium-like fibroblasts; TNFα, tumour
necrosis factor alpha; VEGF, vascular endothelial growth factor
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predictors of radiographic progression. The study found
that patients with low MBDA had significantly less
radiographic progression than patients who meet Dis-
ease Activity Score in 28 joints–CRP European League
Against Rheumatism defined remission. It was also
shown that patients with a high MBDA score were six
times more likely to develop radiographic progression
compared with patients with a high Disease Activity
Score in 28 joints–CRP score, who were only twice as
likely to progress [81].
In conclusion, the MBDA panel has been shown to be
a reliable predictor of joint damage across clinical trials.
It is tempting to speculate that the incorporation of add-
itional serum proteins into this panel might increase its
predictive power. Given the utility of a multi-biomarker
panel demonstrated in RA it is also logical to suggest
that such a panel might prove clinically useful in PsA.
From this literature search it is evident that markers of
angiogenesis and bone remodelling represent strong
candidates. The predictive ability of such markers might
be enhanced if incorporated into a panel with other
newly identified molecules. It is interesting to note some
markers have been identified exclusively in RA and PsA
(Table 2). This identification suggests that distinct
pathological mechanisms underpin joint destruction in
these disorders. However, this might in part be a conse-
quence of the lag in PsA research. The identification of
additional biomarkers, particularly in PsA, should not
only provide us with valuable prognostic information
but also with a greater mechanistic insight into disease
processes. Finally, identifying markers exclusive to one
disease condition would also facilitate the development
of diagnostic assays.
We suggest that the development of MRM assays for
the candidate proteins identified here could be usefully
developed to support the evaluation of multiplexed pro-
tein signatures that could predict joint damage. These
assays could be developed into clinical diagnostic assays
and used routinely in a daily practice and this should
have a significant positive impact on patient care.
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